
Just 1 week after Pfizer and BioNTech’s early Phase III trial data were released, more good news comes from Moderna’s…
Just 1 week after Pfizer and BioNTech’s early Phase III trial data were released, more good news comes from Moderna’s…
In this podcast, Juandem Agendia and Sarah Alexander (NCTC, UK) discuss bacteriophages, the function of the NCTC and the importance…
Phages are a promising alternative to antibiotics, especially considering the looming increase in multidrug-resistant bacteria. This infographic further explores what…
Wednesday 18 November 2020 11:00 [EST] 08:00 [PST] 16:00 [GMT] Alternative time zones REGISTER NOW The pharmaceutical industry is in…
Identifying drugs and developing rapid and accurate diagnostic tests for SARS-CoV-2 are currently at the forefront of the infectious disease…
Bacteriophages (viruses that invade bacteria and can kill them) have gained renewed interest as part of measures to combat the…
In collaboration with the University of Southampton, Synairgen (both Southampton, UK) have announced positive results from their recent trial of SNG001, a novel protein based COVID-19 drug.
In a collaborative study between the University of South Florida (USF Health; FL, USA) and the University of Arizona College of Pharmacy (AZ, USA), several existing drugs have been identified as potential therapies for COVID-19.
The emergence and global spread of SARS-CoV-2 has prompted scientific study on an unprecedented scale, with an urgent need for…
Harvard’s Wyss Institute is leveraging its unique technology innovation capabilities to develop diagnostic, therapeutic, and vaccine interventions for COVID-19 at lightning speed.